Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression

Richard Gorlick, Erdem Goker, Tanya Trippett, Peter Steinherz, Yaroslav Elisseyeff, Madhu Mazumdar, Wayne F. Flintoff, Joseph R. Bertino

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

Methotrexate (MTX) transport was examined in 27 patients with untreated acute lymphocytic leukemia (ALL) and 31 patients with relapsed ALL using a previously described fluorescent MTX analog (PT430) displacement assay (Blood 80:1158, 1992). Only 13% of untreated patients were considered to have impaired MTX transport, whereas more than 70% of relapsed patients had evidence of impaired MTX transport. To further characterize the basis for this defect, Northern analyses for the reduced folate carrier (RFC) were performed on the RNA available from the leukemic blasts of 24 patients in whom MTX transport had been measured. Six of nine samples with impaired MTX transport had decreased RFC expression (one had no detectable RFC expression), while three had no decrease in RFC expression. None of 15 samples with normal MTX transport had decreased RFC expression. A reverse- transcriptase polymerase chain reaction (RT-PCR) assay was developed to quantitate RFC mRNA expression more accurately. Decreased RFC expression was demonstrated in six of the nine samples with impaired MTX transport, confirming the results obtained by Northern blot. These data indicate decreased RFC expression associated with impaired MTX transport is observed in relapsed ALL following treatment with MTX-containing therapy.

Original languageEnglish (US)
Pages (from-to)1013-1018
Number of pages6
JournalBlood
Volume89
Issue number3
StatePublished - Feb 1 1997
Externally publishedYes

Fingerprint

Reduced Folate Carrier Protein
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methotrexate
Assays
Polymerase chain reaction
RNA-Directed DNA Polymerase
Reverse Transcriptase Polymerase Chain Reaction
Northern Blotting
Blood

ASJC Scopus subject areas

  • Hematology

Cite this

Gorlick, R., Goker, E., Trippett, T., Steinherz, P., Elisseyeff, Y., Mazumdar, M., ... Bertino, J. R. (1997). Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood, 89(3), 1013-1018.

Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. / Gorlick, Richard; Goker, Erdem; Trippett, Tanya; Steinherz, Peter; Elisseyeff, Yaroslav; Mazumdar, Madhu; Flintoff, Wayne F.; Bertino, Joseph R.

In: Blood, Vol. 89, No. 3, 01.02.1997, p. 1013-1018.

Research output: Contribution to journalArticle

Gorlick, R, Goker, E, Trippett, T, Steinherz, P, Elisseyeff, Y, Mazumdar, M, Flintoff, WF & Bertino, JR 1997, 'Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression', Blood, vol. 89, no. 3, pp. 1013-1018.
Gorlick, Richard ; Goker, Erdem ; Trippett, Tanya ; Steinherz, Peter ; Elisseyeff, Yaroslav ; Mazumdar, Madhu ; Flintoff, Wayne F. ; Bertino, Joseph R. / Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. In: Blood. 1997 ; Vol. 89, No. 3. pp. 1013-1018.
@article{10c7932008c747dd92804467623d5cb2,
title = "Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression",
abstract = "Methotrexate (MTX) transport was examined in 27 patients with untreated acute lymphocytic leukemia (ALL) and 31 patients with relapsed ALL using a previously described fluorescent MTX analog (PT430) displacement assay (Blood 80:1158, 1992). Only 13{\%} of untreated patients were considered to have impaired MTX transport, whereas more than 70{\%} of relapsed patients had evidence of impaired MTX transport. To further characterize the basis for this defect, Northern analyses for the reduced folate carrier (RFC) were performed on the RNA available from the leukemic blasts of 24 patients in whom MTX transport had been measured. Six of nine samples with impaired MTX transport had decreased RFC expression (one had no detectable RFC expression), while three had no decrease in RFC expression. None of 15 samples with normal MTX transport had decreased RFC expression. A reverse- transcriptase polymerase chain reaction (RT-PCR) assay was developed to quantitate RFC mRNA expression more accurately. Decreased RFC expression was demonstrated in six of the nine samples with impaired MTX transport, confirming the results obtained by Northern blot. These data indicate decreased RFC expression associated with impaired MTX transport is observed in relapsed ALL following treatment with MTX-containing therapy.",
author = "Richard Gorlick and Erdem Goker and Tanya Trippett and Peter Steinherz and Yaroslav Elisseyeff and Madhu Mazumdar and Flintoff, {Wayne F.} and Bertino, {Joseph R.}",
year = "1997",
month = "2",
day = "1",
language = "English (US)",
volume = "89",
pages = "1013--1018",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression

AU - Gorlick, Richard

AU - Goker, Erdem

AU - Trippett, Tanya

AU - Steinherz, Peter

AU - Elisseyeff, Yaroslav

AU - Mazumdar, Madhu

AU - Flintoff, Wayne F.

AU - Bertino, Joseph R.

PY - 1997/2/1

Y1 - 1997/2/1

N2 - Methotrexate (MTX) transport was examined in 27 patients with untreated acute lymphocytic leukemia (ALL) and 31 patients with relapsed ALL using a previously described fluorescent MTX analog (PT430) displacement assay (Blood 80:1158, 1992). Only 13% of untreated patients were considered to have impaired MTX transport, whereas more than 70% of relapsed patients had evidence of impaired MTX transport. To further characterize the basis for this defect, Northern analyses for the reduced folate carrier (RFC) were performed on the RNA available from the leukemic blasts of 24 patients in whom MTX transport had been measured. Six of nine samples with impaired MTX transport had decreased RFC expression (one had no detectable RFC expression), while three had no decrease in RFC expression. None of 15 samples with normal MTX transport had decreased RFC expression. A reverse- transcriptase polymerase chain reaction (RT-PCR) assay was developed to quantitate RFC mRNA expression more accurately. Decreased RFC expression was demonstrated in six of the nine samples with impaired MTX transport, confirming the results obtained by Northern blot. These data indicate decreased RFC expression associated with impaired MTX transport is observed in relapsed ALL following treatment with MTX-containing therapy.

AB - Methotrexate (MTX) transport was examined in 27 patients with untreated acute lymphocytic leukemia (ALL) and 31 patients with relapsed ALL using a previously described fluorescent MTX analog (PT430) displacement assay (Blood 80:1158, 1992). Only 13% of untreated patients were considered to have impaired MTX transport, whereas more than 70% of relapsed patients had evidence of impaired MTX transport. To further characterize the basis for this defect, Northern analyses for the reduced folate carrier (RFC) were performed on the RNA available from the leukemic blasts of 24 patients in whom MTX transport had been measured. Six of nine samples with impaired MTX transport had decreased RFC expression (one had no detectable RFC expression), while three had no decrease in RFC expression. None of 15 samples with normal MTX transport had decreased RFC expression. A reverse- transcriptase polymerase chain reaction (RT-PCR) assay was developed to quantitate RFC mRNA expression more accurately. Decreased RFC expression was demonstrated in six of the nine samples with impaired MTX transport, confirming the results obtained by Northern blot. These data indicate decreased RFC expression associated with impaired MTX transport is observed in relapsed ALL following treatment with MTX-containing therapy.

UR - http://www.scopus.com/inward/record.url?scp=0030948473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030948473&partnerID=8YFLogxK

M3 - Article

VL - 89

SP - 1013

EP - 1018

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -